A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This single arm, open label study will assess the efficacy and safety of and compliance to
treatment with Bonviva/Boniva (ibandronate) in biphosphonate-naïve patients with
post-menopausal osteoporosis. Patients will receive Bonviva/Boniva at a dose of 3 mg
intravenously every three months. Anticipated time on study treatment is 12 months with a
follow-up of 12 months.